Medicina
Departamento
Seoul National University Bundang Hospital
Seongnam-si, Corea del SurPublicaciones en colaboración con investigadores/as de Seoul National University Bundang Hospital (8)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742
-
Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721
-
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075
2022
-
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308
-
ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19
Scientific Data, Vol. 9, Núm. 1
2018
-
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2093-2104